Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Oligonucleotides generated on a microarray provide an abundant source of raw material for assembling long synthetic DNA molecules. Kosuri et al. and Matzas et al. reduce the error rate and improve the scalability of approaches that use microarray oligonucleotides to synthesize genes and other DNA elements (pp 1291 and 1295). Credit: Marina Corral, based on idea courtesy of Sriram Kosuri and Mark Matzas.
The Obama administration's $1 billion tax program at the very least signals a continued commitment to innovative biotech. The same cannot be said of plans afoot by the French government.
The list of drug companies forced into several hundred million dollar settlements for making fraudulent product claims continues to lengthen. And the signs are that the US government will continue to ramp up its efforts, using new theories of liability and handing out even stiffer penalties. Mark Ratner investigates.
Only one drug targeting the proteasome protein degradation pathway has been approved, but several second-generation inhibitors are making progress in trials. Jim Kling reports.
The antiquated legal standard that natural laws and products are not eligible for patent protection is ill-suited for gene and diagnostics patents. Here, I propose a new, technology-agnostic framework for determining patent eligibility that is tailored to the meet the US Constitutional objective of promoting innovation.
Action needs to be taken to prevent anti-biotech activists from co-opting environmental law to derail the planting of transgenic crops that have already received regulatory approval.
First-generation epigenetic drugs have proven clinically useful in several hematological cancers. But newer enzyme inhibitors in the pipeline aim to be more selective and promise to broaden the portfolio of therapeutic uses.
The metabolism of tissues often involves interactions between several types of cell. Lewis et al. model metabolism within and between neurons in the human brain, gaining insight into energy metabolism and Alzheimer's disease.
Minicircle DNA vectors are superior to plasmids for long-term transgene expression but are not in widespread use because of a laborious production process. Kay et al. present an improved protocol for generating minicircles that makes them a viable alternative to plasmids for gene transfer studies.
DNA molecules that are read by a next-generation sequencer have been discarded after the sequencing reaction, until now. By retrieving oil-emulsified beads encapsulating DNA with a known sequence, Matzas et al. obtain high-quality input material for DNA synthesis.
Long DNA molecules, such as those encoding genes, can be assembled from short oligonucleotides created on a microarray. Kosuri et al. improve the fidelity and scalability of this process, enabling synthesis of 40 antibody fragments having repetitive regions and other challenging sequence features.
Nanoparticles are under study for pulmonary drug delivery and are continually in contact with the lungs through air pollution. Choi et al. study the effects of size, charge and chemical composition on the behavior of nanoparticles in the rat lung.
Adaptation of insect pests to tolerate Bacillus thuringiensis (Bt) insecticidal proteins threatens to reduce the efficacy of Bt crops. Evidence from an extensive four-year field trial indicates that the release of sterile pink bollworm moths suppresses the emergence of resistance to transgenic Bt cotton, while helping to eradicate the pest.